Moderna faces revenue declines, regulatory setbacks, and market challenges as COVID-19 vaccine demand wanes. Learn more about ...

At the University of British Columbia, the Blakney Lab is focused on developing vaccines and therapies using self-amplifying ...

Shares of Moderna, Inc. (MRNA) traded over 6% lower on Thursday morning after the company reported a decline in first-quarter ...

Moderna MRNA incurred a loss of $2.52 per share in the first quarter of 2025, narrower than the Zacks Consensus Estimate of a ...

On a Thursday conference call with investors, Moderna CFO Jamey Mock outlined a roadmap for the mRNA specialist to lower its ...

Jefferies analysts said Moderna’s first quarter was “in line,” with a miss on revenue offset by a beat on earnings per share.

Moderna is deprioritizing its flu/COVID combination vaccine in younger adults amid a push to cut about $1.5 billion from its ...

Moderna (MRNA) was in focus Thursday morning after the vaccine maker announced plans to expand its cost efficiency and ...

COVID - 19: The Company reported $84 million in Spikevax® sales in the first quarter of 2025, which includes $29 million of U.S. sales and $55 million of international sales. As previously reported, ...

Moderna logged a first-quarter loss as revenue fell, dragged down by lower product sales, though the company said it expects ...

Moderna on Thursday reported first-quarter profit and sales that beat Wall Street estimates, helped by the company's ...

The US Department of Health and Human Services said it will require that all new vaccines be tested in placebo-controlled ...